These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 12019073)

  • 41. In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model.
    Wicha WW; Craig WA; Andes D
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii5-iii10. PubMed ID: 30949706
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
    Hosaka M; Yasue T; Fukuda H; Tomizawa H; Aoyama H; Hirai K
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2108-17. PubMed ID: 1332587
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacodynamics of cefquinome in a neutropenic mouse thigh model of Staphylococcus aureus infection.
    Wang J; Shan Q; Ding H; Liang C; Zeng Z
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3008-12. PubMed ID: 24614373
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities.
    Firsov AA; Vostrov SN; Shevchenko AA; Portnoy YA; Zinner SH
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2841-7. PubMed ID: 9797213
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.
    Ambrose PG; Forrest A; Craig WA; Rubino CM; Bhavnani SM; Drusano GL; Heine HS
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4351-5. PubMed ID: 17875992
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae.
    Licata L; Smith CE; Goldschmidt RM; Barrett JF; Frosco M
    Antimicrob Agents Chemother; 1997 May; 41(5):950-5. PubMed ID: 9145850
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
    Hershberger E; Rybak MJ
    Antimicrob Agents Chemother; 2000 Mar; 44(3):598-601. PubMed ID: 10681324
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.
    Brueggemann AB; Coffman SL; Rhomberg P; Huynh H; Almer L; Nilius A; Flamm R; Doern GV
    Antimicrob Agents Chemother; 2002 Mar; 46(3):680-8. PubMed ID: 11850248
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
    Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.
    Firsov AA; Vasilov RG; Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH
    J Antimicrob Chemother; 1999 Apr; 43(4):483-90. PubMed ID: 10350376
    [TBL] [Abstract][Full Text] [Related]  

  • 51.
    Zhou YF; Tao MT; Huo W; Liao XP; Sun J; Liu YH
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264844
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.
    Scaglione F; Mouton JW; Mattina R; Fraschini F
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2749-55. PubMed ID: 12936969
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.
    Louie A; Kaw P; Liu W; Jumbe N; Miller MH; Drusano GL
    Antimicrob Agents Chemother; 2001 Mar; 45(3):845-51. PubMed ID: 11181370
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Nakamura R; Ito-Horiyama T; Takemura M; Toba S; Matsumoto S; Ikehara T; Tsuji M; Sato T; Yamano Y
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262762
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance.
    Ba BB; Arpin C; Vidaillac C; Chausse A; Saux MC; Quentin C
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1931-6. PubMed ID: 16723548
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacodynamics of S-3578, a novel cephem, in murine lung and systemic infection models.
    Miyazaki S; Okazaki K; Tsuji M; Yamaguchi K
    Antimicrob Agents Chemother; 2004 Feb; 48(2):378-83. PubMed ID: 14742183
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model.
    MacGowan AP; Rogers CA; Holt HA; Bowker KE
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1088-95. PubMed ID: 12604546
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent.
    Gargallo-Viola D; Ferrer S; Tudela E; Robert M; Coll R; Roser R; Guinea J
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3113-21. PubMed ID: 11600365
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.
    Andes D; Marchillo K; Stamstad T; Conklin R
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3165-9. PubMed ID: 14506026
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.
    Firsov AA; Lubenko IY; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
    J Antimicrob Chemother; 2000 Nov; 46(5):725-32. PubMed ID: 11062191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.